11 Jun 2018
One of the main challenges faced in cancer drug discovery and development, is the selective targeting of malignant cells without impacting on patients' healthy cells. For the first time ever, researchers at the University of Warwick have achieved selective cancer cell death by targeting cancer-specific metabolites using a metal-based catalytic drug. Dr. James Coverdale describes how these so-called 'metallo-catalyst' compounds work and how technologies such as ICP-MS is central to their research concerning metals in medicine.